GB0317466D0 - Use - Google Patents

Use

Info

Publication number
GB0317466D0
GB0317466D0 GBGB0317466.1A GB0317466A GB0317466D0 GB 0317466 D0 GB0317466 D0 GB 0317466D0 GB 0317466 A GB0317466 A GB 0317466A GB 0317466 D0 GB0317466 D0 GB 0317466D0
Authority
GB
United Kingdom
Prior art keywords
mediates
inhibits
medicament
gene
enzyme
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0317466.1A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Sheffield
Original Assignee
University of Sheffield
Newcastle University of Upon Tyne
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27772701&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GB0317466(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by University of Sheffield, Newcastle University of Upon Tyne filed Critical University of Sheffield
Priority to GBGB0317466.1A priority Critical patent/GB0317466D0/en
Publication of GB0317466D0 publication Critical patent/GB0317466D0/en
Priority to HK07100334.8A priority patent/HK1094006B/xx
Priority to AU2004261462A priority patent/AU2004261462B2/en
Priority to PCT/GB2004/003235 priority patent/WO2005012524A1/en
Priority to PL04743516T priority patent/PL1660095T3/pl
Priority to DK04743516.9T priority patent/DK1660095T3/da
Priority to AT04743516T priority patent/ATE454893T1/de
Priority to CA2533423A priority patent/CA2533423C/en
Priority to US10/898,653 priority patent/US7351701B2/en
Priority to PCT/GB2004/003183 priority patent/WO2005012305A2/en
Priority to AT04743564T priority patent/ATE516353T1/de
Priority to US10/555,507 priority patent/US8859562B2/en
Priority to PT04743516T priority patent/PT1660095E/pt
Priority to GB0603874A priority patent/GB2419882B/en
Priority to BRPI0412909-1A priority patent/BRPI0412909B1/pt
Priority to RU2006105652/04A priority patent/RU2404183C2/ru
Priority to KR1020067001650A priority patent/KR101136702B1/ko
Priority to DE602004025123T priority patent/DE602004025123D1/de
Priority to PL04743564T priority patent/PL1649017T5/pl
Priority to AU2004261779A priority patent/AU2004261779B2/en
Priority to JP2006520907A priority patent/JP5519097B2/ja
Priority to MXPA06000993A priority patent/MXPA06000993A/es
Priority to EP04743516A priority patent/EP1660095B1/en
Priority to PT04743564T priority patent/PT1649017E/pt
Priority to CN2004800273183A priority patent/CN1856313B/zh
Priority to CN201210332472.8A priority patent/CN102935230B/zh
Priority to ES04743564.9T priority patent/ES2367433T5/es
Priority to JP2006521648A priority patent/JP5466814B2/ja
Priority to NZ545307A priority patent/NZ545307A/en
Priority to HK06106961.6A priority patent/HK1084602B/en
Priority to NZ544989A priority patent/NZ544989A/en
Priority to KR1020067001725A priority patent/KR101138471B1/ko
Priority to DK04743564.9T priority patent/DK1649017T4/da
Priority to CA2533332A priority patent/CA2533332C/en
Priority to CN2004800272941A priority patent/CN1856572B/zh
Priority to BRPI0412899-0A priority patent/BRPI0412899B1/pt
Priority to US10/565,308 priority patent/US7531530B2/en
Priority to SI200431370T priority patent/SI1660095T1/sl
Priority to EP04743564.9A priority patent/EP1649017B2/en
Priority to ES04743516T priority patent/ES2339663T3/es
Priority to ZA2006/00679A priority patent/ZA200600679B/en
Priority to IL173336A priority patent/IL173336A/en
Priority to ZA200601386A priority patent/ZA200601386B/en
Priority to NO20060906A priority patent/NO338398B1/no
Priority to NO20060928A priority patent/NO334610B1/no
Priority to CY20101100309T priority patent/CY1110335T1/el
Priority to JP2011246988A priority patent/JP5547164B2/ja
Priority to JP2011260401A priority patent/JP5580280B2/ja
Priority to JP2013147532A priority patent/JP5848728B2/ja
Priority to HK13109407.3A priority patent/HK1182016B/xx
Priority to US14/322,759 priority patent/US20150005327A1/en
Priority to US15/650,459 priority patent/US20180000822A1/en
Priority to US16/598,808 priority patent/US20200237762A1/en
Priority to US17/528,034 priority patent/US20220062286A1/en
Ceased legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/55131,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/55171,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/713Double-stranded nucleic acids or oligonucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/005Enzyme inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06Peri-condensed systems
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y204/00Glycosyltransferases (2.4)
    • C12Y204/02Pentosyltransferases (2.4.2)
    • C12Y204/0203NAD+ ADP-ribosyltransferase (2.4.2.30), i.e. tankyrase or poly(ADP-ribose) polymerase
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering nucleic acids [NA]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00Applications; Uses
    • C12N2320/30Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Lubricants (AREA)
GBGB0317466.1A 2003-07-25 2003-07-25 Use Ceased GB0317466D0 (en)

Priority Applications (54)

Application Number Priority Date Filing Date Title
GBGB0317466.1A GB0317466D0 (en) 2003-07-25 2003-07-25 Use
HK07100334.8A HK1094006B (en) 2003-07-25 2004-07-23 Use of rnai inhibiting parp activtiy for the manufacture of a medicament for the treatment of cancer
AU2004261462A AU2004261462B2 (en) 2003-07-25 2004-07-23 Tricyclic PARP inhibitors
PCT/GB2004/003235 WO2005012524A1 (en) 2003-07-25 2004-07-23 Use of rnai inhibiting parp activtiy for the manufacture of a medicament for the treatment of cancer
PL04743516T PL1660095T3 (pl) 2003-07-25 2004-07-23 Tricykliczne inhibitory PARP
DK04743516.9T DK1660095T3 (da) 2003-07-25 2004-07-23 Tricykliske PARP-inhibitorer
AT04743516T ATE454893T1 (de) 2003-07-25 2004-07-23 Tricyclische parp-hemmer
CA2533423A CA2533423C (en) 2003-07-25 2004-07-23 Use of rnai inhibiting parp activity for the manufacture of a medicament for the treatment of cancer
US10/898,653 US7351701B2 (en) 2003-07-25 2004-07-23 Therapeutic compounds
PCT/GB2004/003183 WO2005012305A2 (en) 2003-07-25 2004-07-23 Tricyclic parp inhibitors
AT04743564T ATE516353T1 (de) 2003-07-25 2004-07-23 Verwendung von rnai mit inhibierender parp aktivität zur herstelllung eines arzneimittels zur behandlung von krebs
US10/555,507 US8859562B2 (en) 2003-07-25 2004-07-23 Use of RNAI inhibiting PARP activity for the manufacture of a medicament for the treatment of cancer
PT04743516T PT1660095E (pt) 2003-07-25 2004-07-23 Inibidores tricíclicos de parp
GB0603874A GB2419882B (en) 2003-07-25 2004-07-23 Use of rnai inhibiting parp activity for the manufacture of a medicament for the treatment of cancer
BRPI0412909-1A BRPI0412909B1 (pt) 2003-07-25 2004-07-23 Uso de um inibidor de poli (adp-ribose) polimerase 1 (parp-1) para a fabricação de um medicamento para o tratamento de células de câncer defeituosas em recombinação homóloga
RU2006105652/04A RU2404183C2 (ru) 2003-07-25 2004-07-23 Трициклические ингибиторы парп
KR1020067001650A KR101136702B1 (ko) 2003-07-25 2004-07-23 암 치료용 약제를 제조하기 위한 parp 활성을 억제하는rnai의 용도
DE602004025123T DE602004025123D1 (en) 2003-07-25 2004-07-23 Tricyclische parp-hemmer
PL04743564T PL1649017T5 (pl) 2003-07-25 2004-07-23 Zastosowanie aktywności PARP hamującej RNAI do wytwarzania leku do leczenia raka
AU2004261779A AU2004261779B2 (en) 2003-07-25 2004-07-23 Use of RNAi inhibiting PARP activity for the manufacture of a medicament for the treatment of cancer
JP2006520907A JP5519097B2 (ja) 2003-07-25 2004-07-23 癌を治療するための医薬の製造におけるPARP活性阻害性RNAiの使用
MXPA06000993A MXPA06000993A (es) 2003-07-25 2004-07-23 Inhbidores triciclicos de parp.
EP04743516A EP1660095B1 (en) 2003-07-25 2004-07-23 Tricyclic parp inhibitors
PT04743564T PT1649017E (pt) 2003-07-25 2004-07-23 Utilização de arni inibidor da actividade de parp para o fabrico de um medicamento para tratamento do cancro
CN2004800273183A CN1856313B (zh) 2003-07-25 2004-07-23 治疗化合物
CN201210332472.8A CN102935230B (zh) 2003-07-25 2004-07-23 抑制PARP活性的RNAi用于生产治疗癌症的药物的用途
ES04743564.9T ES2367433T5 (es) 2003-07-25 2004-07-23 Uso de la actividad PARP inhibidora de ARNI para la fabricación de un medicamento para el tratamiento del cáncer
JP2006521648A JP5466814B2 (ja) 2003-07-25 2004-07-23 治療用化合物
NZ545307A NZ545307A (en) 2003-07-25 2004-07-23 Use of RNAI inhibiting parp activity for the manufacture of a medicament for the treatment of cancer
HK06106961.6A HK1084602B (en) 2003-07-25 2004-07-23 Tricyclic parp inhibitors
NZ544989A NZ544989A (en) 2003-07-25 2004-07-23 Tricyclic PARP inhibitors
KR1020067001725A KR101138471B1 (ko) 2003-07-25 2004-07-23 트리시클로 parp 저해제
DK04743564.9T DK1649017T4 (da) 2003-07-25 2004-07-23 Anvendelse af RNA i inhiberende PARP aktivitet til fremstillingen af et lægemiddel til behandlingen af cancer
CA2533332A CA2533332C (en) 2003-07-25 2004-07-23 Therapeutic compounds
CN2004800272941A CN1856572B (zh) 2003-07-25 2004-07-23 抑制PARP活性的RNAi用于生产治疗癌症的药物的用途
BRPI0412899-0A BRPI0412899B1 (pt) 2003-07-25 2004-07-23 Uso de um composto ou um sal farmaceuticamente aceitável do mesmo para a manufatura de um medicamento citotóxico para o tratamento de câncer de ovário, câncer de mama, câncer de próstata ou câncer pancreático
US10/565,308 US7531530B2 (en) 2003-07-25 2004-07-23 Therapeutic compounds
SI200431370T SI1660095T1 (sl) 2003-07-25 2004-07-23 Triciklični parp inhibitorji
EP04743564.9A EP1649017B2 (en) 2003-07-25 2004-07-23 Use of rnai inhibiting parp activity for the manufacture of a medicament for the treatment of cancer
ES04743516T ES2339663T3 (es) 2003-07-25 2004-07-23 Inhibidores de parp triciclicos.
ZA2006/00679A ZA200600679B (en) 2003-07-25 2006-01-24 Therapeutic compounds
IL173336A IL173336A (en) 2003-07-25 2006-01-24 Derivatives of epsilon-lactam fused with indole and benzimidazole for the treatment of cancer caused by a genetic defect in the gene
ZA200601386A ZA200601386B (en) 2003-07-25 2006-02-16 Use of RNAI inhibiting PARP activity for the manufacture of a medicament for the treatment of cancer
NO20060906A NO338398B1 (no) 2003-07-25 2006-02-24 Anvendelse av en poly(ADP-ribose) polymerase (PARP)-inhibitor for fremstilling av et medikament for behandling av cancerceller som er defekte med hensyn på homolog rekombinasjon (HR) og en poly(ADP-ribose) polymerase (PARP)-inhibitor for anvendelse ved behandling av cancerceller som er defekte med hensyn på homolog rekombinasjon (HR).
NO20060928A NO334610B1 (no) 2003-07-25 2006-02-24 Terapeutiske forbindelser og anvendelse av en terapeutisk effektiv mengde av forbindelsene for fremstilling av et cytotoksisk medikament for behandling av kreft, hvor kreften er forårsaket av en genetisk defekt i et gen som medierer homolog rekombinasjon
CY20101100309T CY1110335T1 (el) 2003-07-25 2010-03-31 Τρικυκλικοι αναστολεις parp
JP2011246988A JP5547164B2 (ja) 2003-07-25 2011-11-11 癌を治療するための医薬の製造におけるPARP活性阻害性RNAiの使用
JP2011260401A JP5580280B2 (ja) 2003-07-25 2011-11-29 治療用化合物
JP2013147532A JP5848728B2 (ja) 2003-07-25 2013-07-16 癌を治療するための医薬の製造におけるPARP活性阻害性RNAiの使用
HK13109407.3A HK1182016B (en) 2003-07-25 2013-08-12 Use of rnai inhibiting parp activtiy for the manufacture of a medicament for the treatment of cancer
US14/322,759 US20150005327A1 (en) 2003-07-25 2014-07-02 Use of RNAI Inhibiting PARP Activity for the Manufacture of a Medicament for the Treatment of Cancer
US15/650,459 US20180000822A1 (en) 2003-07-25 2017-07-14 Use of RNAI Inhibiting PARP Activity for the Manufacture of a Medicament for the Treatment of Cancer
US16/598,808 US20200237762A1 (en) 2003-07-25 2019-10-10 Use of rnai inhibiting parp activity for the manufacture of a medicament for the treatment of cancer
US17/528,034 US20220062286A1 (en) 2003-07-25 2021-11-16 Use of rnai inhibiting parp activity for the manufacture of a medicament for the treatment of cancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0317466.1A GB0317466D0 (en) 2003-07-25 2003-07-25 Use

Publications (1)

Publication Number Publication Date
GB0317466D0 true GB0317466D0 (en) 2003-08-27

Family

ID=27772701

Family Applications (2)

Application Number Title Priority Date Filing Date
GBGB0317466.1A Ceased GB0317466D0 (en) 2003-07-25 2003-07-25 Use
GB0603874A Expired - Lifetime GB2419882B (en) 2003-07-25 2004-07-23 Use of rnai inhibiting parp activity for the manufacture of a medicament for the treatment of cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
GB0603874A Expired - Lifetime GB2419882B (en) 2003-07-25 2004-07-23 Use of rnai inhibiting parp activity for the manufacture of a medicament for the treatment of cancer

Country Status (18)

Country Link
US (5) US8859562B2 (enExample)
EP (1) EP1649017B2 (enExample)
JP (3) JP5519097B2 (enExample)
KR (1) KR101136702B1 (enExample)
CN (3) CN1856313B (enExample)
AT (1) ATE516353T1 (enExample)
AU (1) AU2004261779B2 (enExample)
BR (1) BRPI0412909B1 (enExample)
CA (1) CA2533423C (enExample)
DK (1) DK1649017T4 (enExample)
ES (1) ES2367433T5 (enExample)
GB (2) GB0317466D0 (enExample)
NO (1) NO338398B1 (enExample)
NZ (1) NZ545307A (enExample)
PL (1) PL1649017T5 (enExample)
PT (1) PT1649017E (enExample)
WO (1) WO2005012524A1 (enExample)
ZA (1) ZA200601386B (enExample)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6956035B2 (en) 2001-08-31 2005-10-18 Inotek Pharmaceuticals Corporation Isoquinoline derivatives and methods of use thereof
BRPI0407757A (pt) 2003-02-28 2006-02-14 Inotek Pharmaceuticals Corp derivados de benzamida tetracìclica e métodos de uso dos mesmos
GB0317466D0 (en) * 2003-07-25 2003-08-27 Univ Sheffield Use
ES2339663T3 (es) 2003-07-25 2010-05-24 Cancer Research Technology Limited Inhibidores de parp triciclicos.
US8071579B2 (en) * 2003-12-01 2011-12-06 The Institute Of Cancer Research: Royal Cancer Hospital DNA damage repair inhibitors for the treatment of cancer
WO2006078503A2 (en) * 2005-01-07 2006-07-27 Arqule, Inc. Compositions for modulation of parp and methods for screening for same
US7820668B2 (en) 2005-01-19 2010-10-26 Eisai Inc. Diazabenzo[de]anthracen-3-one compounds and methods for inhibiting PARP
CA2598647A1 (en) 2005-02-25 2006-09-08 Inotek Pharmaceuticals Corporation Tetracyclic amino and carboxamido compounds and methods of use thereof
KR20080039508A (ko) 2005-08-24 2008-05-07 이노텍 파마슈티컬스 코포레이션 인데노이소퀴놀리논 유사체 및 이의 사용 방법
EP1962843B1 (en) * 2005-11-25 2011-02-23 Pharma Mar S.A., Sociedad Unipersonal Use of parp-1 inhibitors
US20090062196A1 (en) * 2006-10-20 2009-03-05 D Andrea Alan Compositions and methods of treating cancer
DK2099442T3 (en) * 2006-12-26 2015-02-16 Pharmacyclics Inc Method of using histone deacetylase inhibitors and monitoring biomarkers in combination therapy
US20100121049A1 (en) 2007-02-28 2010-05-13 Inotek Pharmaceuticals Corporation Indenoisoquinolinone analogs and methods of use thereof
GB0707556D0 (en) * 2007-04-19 2007-05-30 Isis Innovation Treatment for cancer
WO2008156172A1 (ja) 2007-06-20 2008-12-24 Saitama Medical University 子宮癌、乳癌、及び膀胱癌の予防乃至治療に好適な二本鎖核酸分子、癌細胞増殖抑制剤、並びに医薬
WO2009027650A1 (en) * 2007-08-24 2009-03-05 The Institute Of Cancer: Royal Cancer Hospital Materials and methods for exploiting synthetic lethality in brca-associated cancers
DK2209375T3 (da) 2007-10-03 2014-10-06 Eisai Inc Parp-inhibitorforbindelser, præparater og fremgangsmåder til anvendelse deraf
WO2009113579A1 (ja) 2008-03-11 2009-09-17 学校法人埼玉医科大学 癌の予防乃至治療に好適な二本鎖核酸分子、癌細胞増殖抑制剤、並びに医薬
US8501431B2 (en) * 2008-10-24 2013-08-06 Magnachem International Laboratories, Inc. Method for screening for compounds selectively interacting with RAD9
US8435961B2 (en) * 2009-06-26 2013-05-07 Massachusetts Institute Of Technology Methods and compositions for increasing the activity of inhibitory RNA
US20110097329A1 (en) 2009-06-26 2011-04-28 Massachusetts Institute Of Technology Compositions and methods for treating cancer and modulating stress granule formation
US8268550B2 (en) * 2009-06-26 2012-09-18 Massachusetts Institute Of Technology Compositions and methods for identification of PARP function, inhibitors, and activators
WO2011058367A2 (en) 2009-11-13 2011-05-19 Astrazeneca Ab Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor
DK3109325T3 (en) 2010-08-24 2019-01-28 Dana Farber Cancer Inst Inc Methods for predicting anticancer response
WO2013052006A1 (en) * 2010-10-07 2013-04-11 Agency For Science, Technology And Research (A*Star) Parp-1 inhibitors
CN110115768A (zh) 2011-07-22 2019-08-13 厄尔莱克斯制药公司 合成致死与癌症的治疗
CA3080441C (en) 2012-02-23 2026-01-06 The Technical University Of Denmark Methods for predicting anti-cancer response
ES2595240T3 (es) 2012-07-09 2016-12-28 Lupin Limited Derivados de tetrahidroquinazolinona como inhibidores de PARP
EP2986709A4 (en) * 2013-04-16 2017-03-15 University Of Washington Through Its Center For Commercialization Activating an alternative pathway for homology-directed repair to stimulate targeted gene correction and genome engineering
EP3049536B1 (en) * 2013-09-23 2019-05-22 The University of Chicago Methods and compositions relating to cancer therapy with dna damaging agents
WO2015118156A1 (en) * 2014-02-07 2015-08-13 Vib Vzw Inhibition of neat1 for treatment of solid tumors
US9889141B2 (en) * 2014-10-14 2018-02-13 Institute For Cancer Research Combined inhibition of the vitamin D receptor and poly(ADP) ribose polymerase (PARP) in the treatment of cancer
PT3277321T (pt) 2015-04-01 2024-09-17 Anaptysbio Inc Anticorpos dirigidos contra a proteína de imunoglobulina de células t e mucina 3 (tim-3)
ES2964607T3 (es) 2015-07-17 2024-04-08 Pacylex Pharmaceuticals Inc Silenciamiento epigenético de NMT2
WO2017054832A1 (en) * 2015-10-02 2017-04-06 University Of Copenhagen Small molecules blocking histone reader domains
ES2847252T3 (es) * 2016-02-22 2021-08-02 Caribou Biosciences Inc Procedimientos de modulación de resultados de reparación de ADN
CA3041685A1 (en) 2016-11-01 2018-05-11 Anaptysbio, Inc. Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3)
KR102671283B1 (ko) 2017-01-09 2024-06-03 테사로, 인코포레이티드 항tim-3 항체로 암을 치료하는 방법
CN107058233A (zh) * 2017-05-03 2017-08-18 上海长海医院 一种减小肿瘤细胞对抗肿瘤药物的耐药性的方法
CN108048465A (zh) * 2017-12-20 2018-05-18 李风玲 一种抑制PARP基因用于治疗乳腺癌的siRNA
WO2019133864A1 (en) 2017-12-29 2019-07-04 Accutar Biotechnology DUAL INHIBITORS OF PARP1 and CDK
TWI820077B (zh) 2018-01-05 2023-11-01 美商斯布雷克薩一號公司 治療涉及酸性或缺氧性患病組織之疾病之化合物、組合物及方法
CR20210281A (es) 2018-10-30 2021-10-25 Repare Therapeutics Inc Compuestos, composiciones farmacéuticas y métodos de preparación de compuestos y de uso como inhibidores de la cinasa atr
PH12021552205A1 (en) * 2019-03-25 2022-06-13 Cyteir Therapeutics Inc Combinations of rad51 and parp inhibitors
KR20220052918A (ko) 2019-07-10 2022-04-28 싸이브렉사 2, 인크. 치료제로서의 사이토톡신의 펩티드 접합체
KR20220051332A (ko) 2019-07-10 2022-04-26 싸이브렉사 3, 인크. 치료제로서의 미세소관 표적화제의 펩티드 접합체
CA3161892A1 (en) 2019-12-23 2021-07-01 Jie Fan Combinations of estrogen receptor degraders and cyclin-dependent kinase inhibitors for treating cancer
FI4143182T3 (fi) 2020-04-28 2025-03-04 Rhizen Pharmaceuticals Ag Poly(adp-riboosi)polymeraasin (parp) estäjinä käyttökelpoisia uusia yhdisteitä
WO2022090938A1 (en) 2020-10-31 2022-05-05 Rhizen Pharmaceuticals Ag Phthalazinone derivatives useful as parp inhibitors
CN114836472A (zh) * 2021-02-01 2022-08-02 中国人民解放军军事科学院军事医学研究院 PARP-1shRNA重组慢病毒载体、该载体稳定转染HaCaT的细胞系及其应用
BR112023020615A2 (pt) 2021-04-08 2023-12-19 Incozen Therapeutics Pvt Ltd Inibidores de poli(adp-ribose) polimerase
JP2024518509A (ja) 2021-05-18 2024-05-01 オンコニック セラピューティクス インコーポレイテッド Parp阻害剤抵抗性癌治療剤
US20250019708A1 (en) * 2021-11-19 2025-01-16 Institut Curie Methods for the treatment of hrd cancer and brca-associated cancer
WO2023201338A1 (en) 2022-04-15 2023-10-19 Ideaya Biosciences, Inc. Combination therapy comprising a mat2a inhibitor and a parp inhibitor
JP2025521156A (ja) 2022-06-01 2025-07-08 イデアヤ、バイオサイエンシズ、インコーポレイテッド Dnaポリメラーゼシータ阻害剤としてのチアジアゾリル誘導体およびその使用
WO2024194401A1 (en) * 2023-03-21 2024-09-26 Institut Curie Vps4b inhibitor for use in methods for the treatment of hrd cancer
WO2024194402A1 (en) * 2023-03-21 2024-09-26 Institut Curie Farnesyl transferase inhibitor for use in methods for the treatment of hrd cancer
AU2024265078A1 (en) 2023-05-04 2025-12-11 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025183523A1 (ko) * 2024-02-29 2025-09-04 아주대학교 산학협력단 Parp 억제제 감수성 증가 방법
WO2025217307A1 (en) 2024-04-09 2025-10-16 Revolution Medicines, Inc. Methods for predicting response to a ras(on) inhibitor and combination therapies
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5484951A (en) 1990-10-19 1996-01-16 Octamer, Incorporated 5-iodo-6-amino-6-nitroso-1,2-benzopyrones useful as cytostatic and antiviral agents
US5098861A (en) 1991-01-08 1992-03-24 Unitrode Corporation Method of processing a semiconductor substrate including silicide bonding
US5464871A (en) 1993-05-12 1995-11-07 Octamer, Inc. Aromatic nitro and nitroso compounds and their metabolites useful as anti-viral and anti-tumor agents
EP0600831A1 (de) 1992-11-27 1994-06-08 Ciba-Geigy Ag Phthalazinonderivate
GB9404485D0 (en) 1994-03-09 1994-04-20 Cancer Res Campaign Tech Benzamide analogues
AU8784698A (en) * 1997-08-15 1999-03-08 Johns Hopkins University, The Method of using selective parp inhibitors to prevent or treat neurotoxicity
CA2360003C (en) 1999-01-11 2012-07-10 Agouron Pharmaceuticals, Inc. Tricyclic inhibitors of poly(adp-ribose) polymerases
US6635677B2 (en) 1999-08-13 2003-10-21 Case Western Reserve University Methoxyamine combinations in the treatment of cancer
ECSP003637A (es) * 1999-08-31 2002-03-25 Agouron Pharma Inhibidores triciclicos de poli (adp-ribosa) polimerasas
DE10022925A1 (de) 2000-05-11 2001-11-15 Basf Ag Substituierte Indole als PARP-Inhibitoren
KR20030020450A (ko) * 2000-08-08 2003-03-08 사노피-신델라보 벤지미다졸 유도체, 그의 제조 방법 및 치료적 용도
MXPA03003218A (es) 2000-10-30 2004-12-03 Kudos Pharm Ltd Derivados de ftalazinona.
DE60218458T2 (de) 2001-05-08 2007-11-15 Kudos Pharmaceuticals Ltd. Isochinolinon derivate als parp inhibitoren
US7072771B2 (en) * 2001-06-07 2006-07-04 University Of Kentucky Research Foundation Selective PARP-1 targeting for designing chemo/radio sensitizing agents
US20030073692A1 (en) 2001-08-07 2003-04-17 Pharmacia & Upjohn S.P.A. Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them
AUPS019702A0 (en) 2002-01-29 2002-02-21 Fujisawa Pharmaceutical Co., Ltd. Condensed heterocyclic compounds
US20030229004A1 (en) 2002-03-20 2003-12-11 Pangene Corporation Modulation of tumor cells using BER inhibitors in combination with a sensitizing agent and DSBR inhibitors
JP4500161B2 (ja) 2002-04-30 2010-07-14 クドス ファーマシューティカルズ リミテッド フタラジノン誘導体
WO2004008976A1 (en) 2002-07-19 2004-01-29 Osteotech, Inc. Chisels and procedure for insertion of spinal implant in a spinal disc space
HRP20050895B1 (hr) * 2003-03-12 2014-06-06 Kudos Pharmaceuticals Limited Ftalazinon derivati
US7176188B2 (en) 2003-05-07 2007-02-13 UniversitéLaval Method of lethally sensitizing human and animal cells
ES2339663T3 (es) * 2003-07-25 2010-05-24 Cancer Research Technology Limited Inhibidores de parp triciclicos.
GB0317466D0 (en) * 2003-07-25 2003-08-27 Univ Sheffield Use
US8071579B2 (en) 2003-12-01 2011-12-06 The Institute Of Cancer Research: Royal Cancer Hospital DNA damage repair inhibitors for the treatment of cancer

Also Published As

Publication number Publication date
CA2533423C (en) 2014-07-22
JP2012102099A (ja) 2012-05-31
ATE516353T1 (de) 2011-07-15
EP1649017A1 (en) 2006-04-26
JP2014001210A (ja) 2014-01-09
CA2533423A1 (en) 2005-02-10
EP1649017B1 (en) 2011-07-13
CN1856313A (zh) 2006-11-01
BRPI0412909A (pt) 2006-09-26
AU2004261779B2 (en) 2008-07-24
KR101136702B1 (ko) 2012-04-20
US20200237762A1 (en) 2020-07-30
PL1649017T5 (pl) 2015-02-27
CN102935230B (zh) 2016-08-10
GB0603874D0 (en) 2006-04-05
US20150005327A1 (en) 2015-01-01
ES2367433T5 (es) 2014-11-03
JP5519097B2 (ja) 2014-06-11
CN102935230A (zh) 2013-02-20
AU2004261779A1 (en) 2005-02-10
JP2006528618A (ja) 2006-12-21
WO2005012524A1 (en) 2005-02-10
US20220062286A1 (en) 2022-03-03
JP5547164B2 (ja) 2014-07-09
BRPI0412909B1 (pt) 2022-04-12
HK1094006A1 (en) 2007-03-16
GB2419882A (en) 2006-05-10
NZ545307A (en) 2009-08-28
ES2367433T3 (es) 2011-11-03
CN1856572B (zh) 2013-11-06
EP1649017B2 (en) 2014-08-27
DK1649017T3 (da) 2011-10-17
NO338398B1 (no) 2016-08-15
US20180000822A1 (en) 2018-01-04
US20070179160A1 (en) 2007-08-02
ZA200601386B (en) 2007-04-25
DK1649017T4 (da) 2014-12-01
CN1856572A (zh) 2006-11-01
HK1182016A1 (zh) 2013-11-22
PL1649017T3 (pl) 2011-12-30
JP5848728B2 (ja) 2016-01-27
GB2419882B (en) 2008-04-09
NO20060906L (no) 2006-04-25
KR20060052877A (ko) 2006-05-19
PT1649017E (pt) 2011-09-30
US8859562B2 (en) 2014-10-14
CN1856313B (zh) 2011-01-12

Similar Documents

Publication Publication Date Title
GB0317466D0 (en) Use
WO2009045356A8 (en) Microrna compositions in the treatment of vegf-mediated disorders
WO2007022506A3 (en) Methods and compositions for treating neurological disease
AU2007257423A8 (en) Purine analogs
TW200637522A (en) Skin treatment articles and methods
TW200610756A (en) Indazoles substitues, compositions les contenant, procede de fabrication et utilisation
NL300874I2 (nl) Elosulfase alfa
EP2493507A4 (en) AX213 AND AX132 PCSK9 ANTAGONISTS AND VARIANTS THEREOF
ZA200809250B (en) Tetrahydropyrrolopyrimidinediones and their use as human neutrophil elastase inhibitors
MY173994A (en) Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
TNSN08140A1 (enExample)
MX341838B (es) Producción de una n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada y sus usos.
SG170819A1 (en) Methods for the production of functional protein from dna having a nonsense mutation and the treatment of disorders associated therewith
MX2010001993A (es) Metodos y composiciones para diagnosticar una enfermedad.
EP2388317A4 (en) GENE ENCODING A MUTANT OF HUMAN GLUCOKINASE, ENZYME CODED THEREOF, RECOMBINANT VECTORS AND RECOMBINANT HOSTS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF, METHODS OF TREATMENT AND PREVENTION OF DISEASES
SG161286A1 (en) Methods for treating and preventing fibrosis by il-21 / il-21r antagonists
MX349364B (es) Variante de alfa-1 antitripsina novedosa, método de preparación de la misma, y uso de la misma.
IL194353A0 (en) Lysobactin amides
UA86399C2 (ru) Применение 2,5 дигидроксибензолсульфоновой кислоты для изготовления лекарства, которые применяют для лечения болезней, зависимых от ангиогенеза
NO20070780L (no) Celloverflateprotein.
UA96926C2 (ru) Применение sdf-1 для лечения и/или профилактики неврологических заболеваний
TW200716153A (en) Mitotic kinesin inhibitors and methods of use thereof
TW200738752A (en) Modulation of MDL-1 activity for treatment of inflammatory disease
DE502005005652D1 (de) Heterocyclyl-substituierte nonadepsipeptide
IL183926A0 (en) PHARMACEUTICAL COMPOSITIONS FOR TREATING DISEASES ASSOCIATED WITH NF-kB ACTIVITY

Legal Events

Date Code Title Description
COOA Change in applicant's name or ownership of the application

Owner name: UNIVERSITY OF SHEFFIELD, THE

Free format text: FORMER APPLICANT(S): UNIVERSITY OF SHEFFIELD, THE;UNIVERSITY OF NEWCASTLE UPON, THE TYNE

AT Applications terminated before publication under section 16(1)